A New Drug Application was submitted to the FDA for a novel, nonhormonal dual neurokinin-1 and neurokinin-3 receptor antagonist for the treatment of menopause-related vasomotor symptoms.
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
Peri- and post-menopausal women frequently complain of insomnia or poor sleep quality. Sleep disturbance is often attributed to nocturnal hot flashes; however, a sizeable proportion of menopausal women may have a primary sleep disorder. Â Â Â As [...]
Over the last few years, we have seen a number of articles suggesting that the burden of menopausal symptoms is probably greater than generally perceived.  About 80% of women experience vasomotor symptoms (VMS) – hot [...]
Many women report cognitive difficulties — forgetfulness, distractibility, feeling foggy — as they enter into the menopause. Looking at sex-related differences in memory, Rentz and colleagues examined 212 men and women between the ages of [...]
Soy-based products have long been touted as a treatment for menopausal symptoms. However, many of the clinical studies measuring the effectiveness of dietary sources of soy isoflavones (e.g., soy beverages, soy powder) for the treatment of menopausal vasomotor symptoms (i.e., hot flushes, night sweats) have been negative. Less is known about the effects of soy on cognition. A large clinical trial suggests that soy may not have any positive effects on cognition in postmenopausal women.
Last Friday, Wyeth received FDA approval for the antidepressant desvenlafaxine succinate (marketed under the name Pristiq), a metabolite of venlafaxine or Effexor. Although this drug was approved for the treatment of major depression, a recent study has demonstrated that desvenlafaxine could be an effective treatment for vasomotor symptoms in postmenopausal women.
